Classement en actions
#19830
Alpha Cognition Inc., a biopharmaceutical company, engages in the development... Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.
Capitalisation boursière
$149.33M
Changement (1 jour)
-1.39%
Échange Alpha Cognition Inc (ACOG)
Le prix ACOG avec la capitalisation boursière de B
Capitalisation boursière de Alpha Cognition Inc(ACOG)
Capitalisation boursière: $149.33M
En August 2026, Alpha Cognition Inc a une capitalisation boursière de $149.33M. Cela fait de Alpha Cognition Inc la 19830th entreprise la plus valorisée au monde selon nos données. La capitalisation boursière, souvent appelée market cap, correspond à la valeur totale des actions en circulation d’une entreprise cotée en bourse, et est couramment utilisée pour évaluer sa valeur.
Historique de la capitalisation boursière de Alpha Cognition Inc du 2024 au 2026
ACOG par rapport au top 5 des plus populaires stocks
| Prix pour ACOG |
|
L’actif B |
La capitalisation boursière de B |
Résultats |
|
|
|
|
$5.152T
|
+3,450,396.58%
|
|
|
|
|
$4.537T
|
+3,038,233.58%
|
|
|
|
|
$4.169T
|
+2,791,489.37%
|
|
|
|
|
$3.642T
|
+2,439,094.36%
|
|
|
|
|
$2.805T
|
+1,878,142.65%
|
